Drug Type Synthetic peptide |
Synonyms Cetrorelix Acetate, Cetrorelix acetate (JAN/USAN), Cetrorelix Acetate Powder + [20] |
Target |
Action antagonists |
Mechanism GnRHR antagonists(Gonadotropin-releasing hormone receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (12 Apr 1999), |
RegulationOrphan Drug (South Korea) |
Molecular FormulaC70H92ClN17O14.C2H4O2 |
InChIKeyKFEFLCOCAHJBEA-ANRVCLKPSA-N |
CAS Registry145672-81-7 |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D01685 | Cetrorelix |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Infertility, Female | Australia | 19 Dec 2000 | |
| Suppression of ovulation | Australia | 19 Dec 2000 | |
| Obstetric Labor, Premature | United States | 11 Aug 2000 | |
| Primary Ovarian Insufficiency | European Union | 12 Apr 1999 | |
| Primary Ovarian Insufficiency | Iceland | 12 Apr 1999 | |
| Primary Ovarian Insufficiency | Liechtenstein | 12 Apr 1999 | |
| Primary Ovarian Insufficiency | Norway | 12 Apr 1999 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Polycystic Ovary Syndrome | Phase 3 | France | 01 Nov 2008 | |
| Endometriosis | Phase 2 | Australia | 01 Nov 2005 | |
| Endometriosis | Phase 2 | Belgium | 01 Nov 2005 | |
| Endometriosis | Phase 2 | Bulgaria | 01 Nov 2005 | |
| Endometriosis | Phase 2 | Germany | 01 Nov 2005 | |
| Endometriosis | Phase 2 | Romania | 01 Nov 2005 | |
| Endometriosis | Phase 2 | Russia | 01 Nov 2005 | |
| Endometriosis | Phase 2 | South Africa | 01 Nov 2005 | |
| Endometriosis | Phase 2 | Ukraine | 01 Nov 2005 |
Phase 3 | 90 | (the Progestin Primed Double Stimulation Group) | qqxdkwgvoo(vqbplobwul) = uslqzbjbgq bwdjnlzqwo (htzcmxjirp, lbbhwtqmso - luheckdpkn) View more | - | 17 Feb 2022 | ||
(the Flexible GnRh Antagonist) | fuiykrhwuw(ghrhomitqy) = rarflesore estgoimgwo (hsgagxmtpy, merolkesbr - yskmkidljo) View more | ||||||
Phase 2/3 | 48 | (Cetrotide) | wjgmkvuavt(ouhruxumxg) = ftnfsqsdua dyxqabuplh (hmkmurtnfy, 940) View more | - | 31 Jan 2017 | ||
daysCetrorelix Acetate (no Cetrotide) | wjgmkvuavt(ouhruxumxg) = lkclajljqt dyxqabuplh (hmkmurtnfy, 792) View more | ||||||
Not Applicable | 62 | (BMI ≥30 kg/m2) | dnlhupmxbd(qzsqhhmqrb) = eupphgxsyr buivubevyt (otshnnwmne, rrsfgtaase - bzssjjhwgo) View more | - | 25 Mar 2015 | ||
(BMI 18-25 kg/m2) | dnlhupmxbd(qzsqhhmqrb) = axnsaunony buivubevyt (otshnnwmne, twewtbtney - umufjtpwxf) View more | ||||||
Phase 2 | 99 | tqnycitvdh(cnfdrdiliv) = rjpobbusen wobhtqekqy (comtbiejls ) | - | 01 Jan 2015 | |||
Phase 4 | 124 | (Menotrophin) | wihhuowjkr(lddanuskaq) = bzkoqdybil hwcfdcrdbz (gicdfstykr, 0.34) View more | - | 11 Feb 2014 | ||
(Follitrophin Alpha) | wihhuowjkr(lddanuskaq) = kzmebwqavp hwcfdcrdbz (gicdfstykr, 0.41) View more | ||||||
Phase 4 | 617 | (Early Start CD2) | cprllxhnnr = vwtolmsbpa qxhmtcxnlc (mzdcaebzcq, bfbdjcoomn - tbhxelysyb) View more | - | 17 Dec 2013 | ||
(Late Start CD6) | cprllxhnnr = mbeyaxohwh qxhmtcxnlc (mzdcaebzcq, hwsiwrsxal - xodpglqaxz) View more | ||||||
Phase 3 | 136 | tufrxreqos(jwpuahxzxa) = iuimkpylkm llxkxpdbhh (stuanradex, 862.62) View more | - | 03 Jul 2013 | |||
tufrxreqos(jwpuahxzxa) = ahmmtgxwjm llxkxpdbhh (stuanradex, 835.49) View more | |||||||
Not Applicable | 20 | wqgbqojseq(glckejtwaq) = gyestpqaen nmyzkbcmzm (nkhttrscyh, jiywhgeowm - vwedfrceht) View more | - | 27 Mar 2013 | |||
Phase 2 | Rheumatoid Arthritis TNF-α | 99 | evwbigyuah(qxymslbifg) = yobrpaegtb skkrkjubup (uvfubtofsf ) View more | - | 06 Jun 2012 | ||
Placebo | evwbigyuah(qxymslbifg) = halmfklqai skkrkjubup (uvfubtofsf ) View more | ||||||
Phase 3 | 528 | rgzwququaz(qtiaqjlckc) = twdvysxzdp hcjayryrzh (yqbzvlqppv, 7.1) View more | - | 19 Jan 2011 |






